On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna had been awarded over $750 million to develop a vaccine against bird flu, which has been circulating in farm animals and sickening people.

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.